Cell Biotech Co

Cell Biotech Co Treasury Stock

The Treasury Stock of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 422.69 M KRW. In the previous year, Treasury Stock was 231.83 M KRW — a change of 82.32% (higher).

Treasury Stock

422.69 MKRW

YoY

82.32%

Last updated:

Treasury Stock of Cell Biotech Co is 2024 422.69 M KRW. Treasury Stock of Cell Biotech Co was 2023 231.83 M KRW. It decreases by 82.32% higher compared to the previous year.

The Cell Biotech Co Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2017
-214.29 M KRW
Jan 1, 2018
-23.38 M KRW
Jan 1, 2019
-53.66 M KRW
Jan 1, 2020
86.97 M KRW
Jan 1, 2021
-408.42 M KRW
Jan 1, 2022
33.40 M KRW
Jan 1, 2023
231.83 M KRW
Jan 1, 2024
422.69 M KRW
The Cell Biotech Co Treasury Stock history
YEARTreasury StockYoY
422.69 MKRW+82.32%
231.83 MKRW+594.06%
33.40 MKRW-108.18%
-408.42 MKRW-569.61%
86.97 MKRW-262.09%
-53.66 MKRW+129.50%
-23.38 MKRW-89.09%
-214.29 MKRW-740.56%
33.45 MKRW-37.46%
53.49 MKRW-4,595.72%
-1.19 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Treasury Stock of Cell Biotech Co is 422.69 M KRW in 2024.

Treasury Stock of Cell Biotech Co changed from 231.83 M KRW to 422.69 M KRW, representing a 82.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Cell Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cell Biotech Co

All Key Metrics — Cell Biotech Co